PARFIANOWICZ, Agnieszka and ALICJA SURMA. GLP-1 and SGLT2 Therapies in Type 2 Diabetes Mellitus. Cutting-Edge Approaches to Advancing Diabetes Care. Journal of Education, Health and Sport. 2025;78:57478. eISSN 2391-8306.
https://doi.org/10.12775/JEHS.2025.78.57478
https://apcz.umk.pl/JEHS/article/view/57478

The journal has had 40 points in Minister of Science and Higher Education of Poland parametric evaluation. Annex to the announcement of the Minister of Education and Science of 05.01.2024 No. 32318. Has a Journal's Unique Identifier: 201159. Scientific disciplines assigned: Physical culture sciences (Field of medical and health sciences); Health Sciences (Field of medical and health sciences).
Punkty Ministerialne 40 punktów. Załącznik do komunikatu Ministra Nauki i Szkolnictwa Wyższego z dnia 05.01.2024 Lp. 32318. Posiada Unikatowy Identyfikator Czasopisma: 201159. Przypisane dyscypliny naukowe: Nauki o kulturze fizycznej (Dziedzina nauk medycznych i nauk o zdrowiu); Nauki o zdrowiu (Dziedzina nauk medycznych i nauk o zdrowiu).
The authors declare that there is no conflict of interests regarding the publication of this paper.
Received: 31.12.2024. Revised: 02.02.2025. Accepted: 04.02.2025. Published: 04.02.2025.

GLP-1 and SGLT2 Therapies in Type 2 Diabetes Mellitus. Cutting-Edge Approaches to Advancing Diabetes Care

Agnieszka Parfianowicz, District Hospital in Sochaczew,

ul.Batalionów Chłopskich 3/7, 96-500 Sochaczew, Poland

https://orcid.org/0009-0009-8415-6478

parfianowiczagnieszka@gmail.com

Alicja Surma, Provincial Hospital in Sochaczew,

ul. Batalionów Chłopskich 3/7, 96-500 Sochaczew, Poland

https://orcid.org/0009-0009-3921-478X

a.surma96@gmail.com

Abstract

Type 2 diabetes mellitus (T2DM) is a multifactorial disease characterized by insulin resistance, beta-cell dysfunction, and chronic hyperglycemia. Despite the availability of conventional therapies, significant unmet needs persist in achieving optimal glycemic control and reducing long-term complications. GLP-1 receptor agonists (GLP-1 RAs) and SGLT2 inhibitors represent two novel classes of antidiabetic agents that have transformed the therapeutic

landscape. This paper explores their mechanisms of action, clinical benefits, and potential synergistic effects, emphasizing their impact on cardiovascular and renal outcomes. Challenges and future directions for these agents in personalized diabetes care are also discussed.

Keywords: type 2 diabetes, flozyns, dm 2

Introduction

Type 2 diabetes mellitus (T2DM) is one of the most prevalent chronic metabolic disorders, affecting over 450 million people worldwide, with projections suggesting a further increase to 783 million by 2040. [1] It is characterized by a complex interplay of insulin resistance, progressive beta-cell dysfunction, and hyperglycemia, leading to a cascade of complications that significantly impair quality of life and increase healthcare costs. Beyond glycemic disturbances, T2DM is associated with a heightened risk of cardiovascular diseases (CVD), chronic kidney disease (CKD), and other systemic complications that contribute to its significant morbidity and mortality. [2,3]

Traditional therapies, including metformin, sulfonylureas, and insulin, have been the cornerstone of T2DM management for decades. [4] While effective in lowering blood glucose levels, these treatments often fail to address the multifaceted nature of the disease, such as its cardiovascular and renal dimensions. Additionally, side effects like weight gain and hypoglycemia can compromise adherence, leaving many patients inadequately controlled. [5,6]

In recent years, the introduction of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter 2 (SGLT2) inhibitors has revolutionized the therapeutic landscape of T2DM. These novel drug classes not only improve glycemic control but also provide ancillary benefits, including weight reduction, blood pressure lowering, and protection against cardiovascular and renal complications. [6] These outcomes represent a paradigm shift, moving away from glucose-centric management toward a more comprehensive approach targeting the underlying pathophysiology and long-term complications of the disease. [7]

This paper aims to provide an in-depth exploration of GLP-1 RAs and SGLT2 inhibitors, focusing on their mechanisms of action, clinical efficacy, and real-world impact. By analyzing the synergistic effects of these agents and addressing current challenges, this work highlights their potential to redefine the standard of care in T2DM management.

Pathophysiology of T2DM and Therapeutic Targets

Type 2 diabetes mellitus (T2DM) is a multifactorial and progressive disease arising from a combination of genetic predisposition and environmental factors, including obesity and sedentary lifestyles. It is characterized by several interrelated pathophysiological processes that contribute to chronic hyperglycemia and metabolic dysregulation. [8] Understanding these mechanisms is essential for identifying and developing effective therapeutic targets.

Insulin Resistance and Beta-Cell Dysfunction

One of the hallmarks of T2DM is insulin resistance, where peripheral tissues such as skeletal muscle, adipose tissue, and the liver exhibit a reduced response to insulin. [9] This impairment leads to decreased glucose uptake in muscle cells, increased lipolysis in adipose tissue, and excessive hepatic glucose production, all of which contribute to elevated blood glucose levels. Over time, chronic hyperglycemia and increased insulin demand place significant stress on pancreatic beta cells, resulting in their functional decline and eventual failure. [10]

Beta-cell dysfunction is further exacerbated by glucotoxicity and lipotoxicity, where chronic exposure to high glucose and fatty acid levels damages beta-cell function and survival. This progressive decline in beta-cell capacity impairs the body's ability to compensate for insulin resistance, leading to worsening hyperglycemia. [11]

The Incretin System

The incretin system plays a critical role in glucose homeostasis by modulating insulin secretion in response to nutrient intake. Glucagon-like peptide-1 (GLP-1) is a key incretin hormone secreted by the intestinal L-cells in response to meal ingestion. [12] GLP-1 enhances glucose-dependent insulin secretion, suppresses glucagon release, delays gastric emptying, and promotes satiety. [13] However, in T2DM, the incretin effect is significantly impaired, contributing to inadequate postprandial insulin response and hyperglycemia. [14]

Targeting the GLP-1 pathway has emerged as a promising therapeutic approach to restore the incretin effect. GLP-1 receptor agonists (GLP-1 RAs) mimic the actions of endogenous GLP-1 while being resistant to rapid enzymatic degradation by dipeptidyl peptidase-4 (DPP-4), allowing for sustained biological activity. [15]

Renal Glucose Reabsorption

The kidneys play a vital role in glucose homeostasis, filtering approximately 180 grams of glucose daily in healthy individuals. Under normal conditions, nearly all filtered glucose is reabsorbed in the proximal tubules by sodium-glucose cotransporter 2 (SGLT2). [16] In T2DM, increased renal glucose reabsorption exacerbates hyperglycemia by maintaining elevated plasma glucose levels. [17]

SGLT2 inhibitors target this maladaptive process by blocking the reabsorption of glucose in the proximal tubule, leading to glucosuria. This mechanism not only reduces plasma glucose levels but also promotes weight loss through caloric loss and improves blood pressure via osmotic diuresis. By addressing renal glucose handling, SGLT2 inhibitors provide a unique mechanism of action that is independent of insulin. [18]

Therapeutic Implications

The pathophysiological insights into T2DM have driven the development of novel pharmacological agents targeting these specific pathways. GLP-1 receptor agonists and SGLT2 inhibitors are particularly well-suited to address multiple aspects of T2DM pathophysiology. [19] GLP-1 RAs directly target the incretin system, improving beta-cell function and reducing glucagon secretion, while SGLT2 inhibitors provide an insulin-independent mechanism to lower blood glucose and offer additional cardiovascular and renal benefits.

This understanding has led to a paradigm shift in T2DM management, with these agents becoming integral components of guideline-recommended therapies, particularly for patients with comorbid cardiovascular or renal disease. By addressing the root causes and complications of T2DM, these therapies exemplify the evolution of diabetes care beyond glucose-centric approaches. [20]

GLP-1 Receptor Agonists: Mechanism of action

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as a transformative class of medications in the management of type 2 diabetes mellitus (T2DM) and associated metabolic disorders. These agents are designed to mimic the activity of endogenous GLP-1, an incretin hormone secreted by L-cells in the distal ileum and colon in response to nutrient ingestion. [21]

The primary mechanism of GLP-1 RAs involves their binding to GLP-1 receptors, which are widely expressed throughout the body, including on pancreatic β-cells, α-cells, the gastrointestinal tract, and the central nervous system. By engaging these receptors on pancreatic β-cells, GLP-1 RAs stimulate insulin secretion in a glucose-dependent manner. [22] This ensures that insulin is primarily released when blood glucose levels are elevated, reducing the risk of hypoglycemia—a key advantage over other glucose-lowering therapies. [23] At the same time, these agents inhibit glucagon release by acting on α-cells of the pancreas. Suppressed glucagon secretion reduces hepatic glucose production, further contributing to improved glycemic control. [24]

Another crucial mechanism involves the delay of gastric emptying. By slowing the transit of food from the stomach to the small intestine, GLP-1 RAs reduce the rate of glucose absorption, thereby blunting postprandial glucose excursions. [25] Additionally, GLP-1 RAs exert effects on the central nervous system, particularly the hypothalamus, where they enhance satiety and reduce appetite. This satiety-promoting effect often leads to significant weight loss, an important outcome for individuals with T2DM and obesity. [26]

Beyond their metabolic benefits, GLP-1 RAs have demonstrated impressive cardiovascular protective effects. Trials have shown that liraglutide and semaglutide significantly reduce the risk of major adverse cardiovascular events (MACE), including myocardial infarction, stroke, and cardiovascular death. [27,28] These findings underscore the dual therapeutic role of GLP-1 RAs in managing hyperglycemia and mitigating macrovascular complications, which are prevalent in patients with T2DM.

In conclusion, GLP-1 receptor agonists offer a multifaceted approach to the treatment of type 2 diabetes mellitus. By enhancing glucose-dependent insulin secretion, suppressing glucagon release, delaying gastric emptying, and promoting weight loss, these agents not only improve glycemic control but also address critical cardiovascular risks. Their broad range of benefits positions GLP-1 RAs as a cornerstone in the comprehensive management of T2DM, particularly for patients with obesity and elevated cardiovascular risk profiles

SGLT2 Inhibitors: Mechanism of action

Sodium-glucose co-transporter-2 (SGLT2) inhibitors, including canagliflozin, dapagliflozin, and empagliflozin, have emerged as transformative agents in the treatment of type 2 diabetes mellitus (T2DM), offering benefits that extend beyond glycemic control. [29] drugs act by targeting SGLT2, a protein located in the proximal tubules of the kidney, which plays a critical role in glucose reabsorption. Under normal circumstances, the kidneys filter approximately 180 grams of glucose daily, with the majority reabsorbed into the bloodstream via SGLT2 transporters. By inhibiting this process, SGLT2 inhibitors increase urinary glucose excretion (glucosuria), leading to a reduction in plasma glucose levels. This mechanism, independent of insulin secretion or action, makes these agents particularly advantageous for patients with insulin resistance or those at risk of hypoglycemia. [30,31]

In addition to improving glycemic control, the excretion of glucose through the urine results in a mild diuretic effect, which contributes to reductions in both body weight and blood pressure. [32] Weight loss occurs due to caloric loss from glucosuria, while the blood pressure-lowering effects are attributed to reductions in plasma volume and arterial stiffness. These combined effects make SGLT2 inhibitors a comprehensive therapy for addressing multiple metabolic and cardiovascular risk factors in patients with T2DM. [33]

The clinical benefits of SGLT2 inhibitors extend significantly beyond their metabolic effects. Landmark cardiovascular outcomes trials (CVOTs), such as EMPA-REG OUTCOME for empagliflozin, CANVAS for canagliflozin, and DECLARE-TIMI 58 for dapagliflozin, have demonstrated their ability to reduce the risk of major adverse cardiovascular events (MACE), including myocardial infarction, stroke, and cardiovascular death, particularly in patients with established cardiovascular disease (CVD). [34] Furthermore, SGLT2 inhibitors have shown remarkable efficacy in reducing hospitalization for heart failure, a benefit observed even in patients without diabetes, as evidenced by trials such as DAPA-HF and EMPEROR-Reduced. [35]

Equally noteworthy are the renal protective effects of SGLT2 inhibitors. [36] By reducing intraglomerular pressure and proteinuria, these agents slow the progression of chronic kidney disease (CKD), as demonstrated in studies such as CREDENCE for canagliflozin and DAPA-CKD for dapagliflozin. [37] These trials showed significant reductions in the risk of end-stage kidney disease, renal death, and worsening renal function, highlighting the importance of SGLT2 inhibitors in managing CKD in both diabetic and non-diabetic populations.

SGLT2 inhibitors have thus become a cornerstone in modern diabetes therapy, offering a unique combination of glycemic control, weight loss, blood pressure reduction, cardiovascular protection, and renal preservation. Importantly, many of these benefits occur independently of

glycemic control, underscoring their value even in non-diabetic individuals with high cardiovascular or renal risk. [38, 39] By addressing the multifaceted needs of patients with diabetes and its associated complications, SGLT2 inhibitors represent a paradigm shift in the management of this complex disease.

Additional Benefits of GLP-1 Receptor Agonists and SGLT2 Inhibitors Beyond Glycemic Control

GLP-1 receptor agonists (GLP-1 RAs) and SGLT2 inhibitors offer a range of benefits that extend far beyond their primary role in glycemic control, positioning them as indispensable tools in the comprehensive management of type 2 diabetes mellitus (T2DM). These pleiotropic effects address key comorbidities associated with T2DM, significantly enhancing their therapeutic value. [40]

Both drug classes have demonstrated profound cardiovascular benefits, though their mechanisms and specific impacts differ. GLP-1 RAs, such as liraglutide and semaglutide, have been shown in major cardiovascular outcome trials, including LEADER and SUSTAIN-6, to reduce major adverse cardiovascular events (MACE) such as myocardial infarction and stroke. [41,42] They also significantly decrease cardiovascular mortality in high-risk patients. [43] These effects are thought to arise from improvements in vascular function and reductions in inflammation. In comparison, SGLT2 inhibitors, such as empagliflozin and dapagliflozin, have consistently demonstrated robust benefits in reducing hospitalization for heart failure and cardiovascular death, as evidenced by trials like EMPA-REG OUTCOME and DAPA-HF. [34,35] These cardiovascular effects are attributed to their ability to reduce preload and afterload through mechanisms such as osmotic diuresis and natriuresis, which improve cardiac function and volume status. [44]

Renal protection is another shared benefit of these drug classes, though SGLT2 inhibitors exhibit particularly remarkable efficacy in this area. While GLP-1 RAs have shown promise in slowing the progression of diabetic nephropathy by reducing albuminuria and improving renal hemodynamics, SGLT2 inhibitors stand out for their ability to reduce intraglomerular pressure and slow the decline in glomerular filtration rate (GFR). [45, 46] Landmark trials, including CREDENCE for canagliflozin and DAPA-CKD for dapagliflozin, have demonstrated that these agents not only delay the progression of chronic kidney disease (CKD) in patients with diabetes but also confer renal benefits in individuals without diabetes, broadening their utility. [37,47]

Both drug classes contribute to weight loss and metabolic improvements, albeit through distinct mechanisms. GLP-1 RAs are particularly effective in promoting significant weight reduction, primarily by enhancing satiety and reducing caloric intake. [48] This makes them especially valuable for overweight or obese individuals with T2DM. In contrast, the weight loss associated with SGLT2 inhibitors is more modest and is achieved through caloric loss due to glucosuria. Despite these differences, the combination of these agents can yield synergistic benefits, enhancing metabolic health in patients. [49]

Blood pressure reduction is another area where both GLP-1 RAs and SGLT2 inhibitors have demonstrated benefits, though the mechanisms again differ. GLP-1 RAs exert modest effects on lowering systolic blood pressure, likely driven by their impact on weight loss and improved

vascular function. [50] On the other hand, SGLT2 inhibitors directly lower blood pressure through osmotic diuresis and natriuresis, a property that is particularly advantageous for T2DM patients with coexisting hypertension. [51]

Finally, both drug classes have shown potential anti-inflammatory and vascular effects, further contributing to their cardiovascular and renal benefits. GLP-1 RAs have been associated with improved endothelial function and reductions in markers of systemic inflammation, such as C-reactive protein (CRP). [52] Similarly, SGLT2 inhibitors may exert anti-inflammatory and antioxidative effects by modulating metabolic stress and reducing oxidative damage in tissues. [53]

In summary, while both GLP-1 RAs and SGLT2 inhibitors share overlapping benefits in cardiovascular and renal protection, weight loss, blood pressure reduction, and anti-inflammatory effects, their distinct mechanisms of action and specific advantages make them complementary in the treatment of T2DM. Together, these agents provide a holistic approach to managing the multifaceted complications of diabetes, addressing not only glycemic control but also the critical comorbidities that drive morbidity and mortality in this population.

Challenges and Considerations in the Use of GLP-1 RAs and SGLT2 Inhibitors

While GLP-1 receptor agonists (GLP-1 RAs) and SGLT2 inhibitors offer substantial benefits in the management of type 2 diabetes mellitus (T2DM), their use is accompanied by notable challenges and limitations. These issues encompass both clinical and practical aspects, including side effects, costs, accessibility, and patient adherence. Addressing these challenges is critical to optimizing the use of these therapies.

One of the primary drawbacks of GLP-1 RAs is their association with gastrointestinal side effects, which are particularly common in the initial stages of treatment. Patients often report nausea, vomiting, diarrhea, or abdominal discomfort, which can impair adherence to the therapy. [54]These side effects are believed to result from the delayed gastric emptying caused by GLP-1 RAs, a key mechanism through which these drugs promote satiety and weight loss. While the gastrointestinal effects tend to diminish over time as patients adapt to the medication, for some individuals, these adverse events may be severe enough to necessitate discontinuation of therapy. [55] Additionally, there have been reports of rare but serious adverse events, such as pancreatitis, though the causal relationship remains under investigation.

SGLT2 inhibitors, on the other hand, present a distinct set of side effects. The most common adverse events are genitourinary infections, such as fungal infections and urinary tract infections, resulting from the increased glucose concentration in the urine. [56] These infections are typically mild but can be recurrent and bothersome for patients. More concerning, albeit rare, is the risk of euglycemic diabetic ketoacidosis (DKA), a potentially life-threatening condition characterized by high levels of ketones in the blood despite normal or mildly elevated glucose levels. Patients with certain risk factors, such as insulin deficiency, acute illness, or dehydration, are particularly vulnerable to this complication. [57] Other potential adverse effects of SGLT2 inhibitors include volume depletion and associated hypotension, particularly in elderly patients or those on diuretic therapy. [58]

Beyond side effects, the high cost of GLP-1 RAs and SGLT2 inhibitors poses a significant barrier to their widespread use. These medications are among the most expensive treatments for T2DM, with prices varying by country and healthcare system. For example, in the United States, monthly costs for GLP-1 RAs like liraglutide or semaglutide can exceed $800–$1,000, while SGLT2 inhibitors like empagliflozin or dapagliflozin range from $500–$700 per month. [59] These costs can be prohibitive for patients without adequate insurance coverage or in resource-limited settings, where generic alternatives or government-subsidized programs may not be available. Even in well-resourced healthcare systems, the financial burden on patients and healthcare providers can limit access to these therapies, particularly when combined with other necessary medications for comorbid conditions.

The accessibility challenges are compounded by the need for careful patient selection and monitoring. Both GLP-1 RAs and SGLT2 inhibitors require clinicians to evaluate patient-specific factors before initiation. For GLP-1 RAs, the presence of gastrointestinal disorders, a history of pancreatitis, or contraindications such as medullary thyroid carcinoma necessitate caution. Similarly, for SGLT2 inhibitors, considerations include renal function, as these drugs lose efficacy in patients with advanced chronic kidney disease (CKD) and may exacerbate complications like volume depletion or electrolyte imbalances in vulnerable populations. [60,61]

Comparing the two drug classes, the practical challenges also differ. GLP-1 RAs are often administered via subcutaneous injection, which may be less appealing to patients accustomed to oral medications. This mode of administration can impact adherence and requires patient education on proper injection techniques. [62] In contrast, SGLT2 inhibitors are oral medications, which may enhance patient convenience and compliance. However, the risk of genitourinary infections and ketoacidosis remains a concern, particularly in patients with poor hydration or those at risk of acute kidney injury. [63]

In conclusion, while GLP-1 RAs and SGLT2 inhibitors offer substantial clinical benefits, their use must be balanced against the potential for adverse effects, high costs, and accessibility challenges. Clinicians must carefully evaluate individual patient profiles, including comorbidities, renal function, and financial constraints, to determine the most appropriate therapy. Moreover, the high cost of these medications underscores the need for policy measures to improve affordability and access, especially in underserved populations. By addressing these challenges, the full potential of these innovative therapies can be realized in the fight against T2DM and its associated complications

Future Directions in Diabetes Management

The management of type 2 diabetes mellitus (T2DM) is undergoing a transformation, driven by ongoing research and the development of next-generation therapeutic agents. Among the most promising innovations are dual GLP-1/GIP co-agonists, which represent a new frontier in diabetes care. These agents combine the actions of two incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), to deliver enhanced glycemic control and metabolic benefits. [64] Early clinical trials have shown that dual agonists, such as tirzepatide, offer superior reductions in HbA1c and body weight compared to existing GLP-1 receptor agonists. This novel mechanism of action leverages the

complementary effects of GLP-1 and GIP to enhance insulin secretion, suppress glucagon, and improve insulin sensitivity, while also reducing appetite and promoting weight loss. These advancements suggest that dual agonists may redefine the therapeutic landscape, particularly for patients with obesity and complex metabolic profiles. [65,66]

In addition to next-generation drugs, the application of precision medicine in diabetes care is an exciting and rapidly evolving area. Precision medicine involves tailoring treatment strategies based on an individual's genetic, metabolic, and phenotypic characteristics. [67] Advances in genomic sequencing and metabolomics have begun to unravel the complex heterogeneity of T2DM, revealing distinct subtypes of the disease that may respond differently to various therapies. For example, patients with a predominance of insulin resistance may benefit more from agents targeting weight loss and metabolic improvement, such as GLP-1 RAs or SGLT2 inhibitors, while those with defects in beta-cell function may require therapies that enhance insulin secretion. By integrating genetic and metabolic profiling into routine clinical practice, clinicians could optimize therapeutic choices, minimize adverse effects, and improve long-term outcomes. [68]

Another important area of focus is the evaluation of the long-term benefits and risks associated with these novel agents. While current studies have demonstrated the efficacy of dual GLP-1/GIP agonists and other emerging therapies in achieving short-term glycemic control and weight reduction, their durability and long-term impact on diabetes-related complications remain areas of active investigation. Questions about their potential to prevent or reverse macrovascular and microvascular complications, such as cardiovascular disease, nephropathy, retinopathy, and neuropathy, require further exploration through large-scale, long-term clinical trials. These studies will also help to elucidate whether the benefits observed in early-phase trials are maintained over years of treatment and whether they confer additional protective effects beyond those offered by existing therapies.

Moreover, the integration of digital health technologies is likely to play a pivotal role in the future of diabetes care. Continuous glucose monitoring (CGM) systems, wearable devices, and mobile applications are already enhancing the ability of patients and clinicians to track glycemic trends, monitor medication adherence, and make real-time adjustments to therapy. These technologies, combined with artificial intelligence and machine learning algorithms, could enable the development of highly personalized treatment plans that adapt dynamically to changes in a patient's health status. For example, predictive models could identify individuals at high risk for complications and recommend early interventions to mitigate these risks. [69, 70]

Finally, the accessibility and affordability of these advanced therapies remain critical challenges that must be addressed to ensure their widespread adoption. Despite the remarkable potential of next-generation agents and precision medicine approaches, their high costs may limit availability, particularly in low- and middle-income countries. Addressing these barriers will require collaborative efforts between healthcare providers, pharmaceutical companies, policymakers, and patient advocacy groups. Strategies such as tiered pricing, generic development, and government-subsidized programs could help to bridge the gap between innovation and accessibility, ensuring that all patients with T2DM can benefit from these advances. [71,72]

In summary, the future of diabetes care is marked by exciting developments in pharmacology, precision medicine, and digital health. The emergence of dual GLP-1/GIP co-agonists and other novel agents holds promise for improving glycemic control and addressing the broader metabolic challenges of T2DM. At the same time, the integration of genetic and metabolic profiling, combined with advances in technology, offers a pathway to truly personalized and dynamic diabetes management. While challenges related to cost, access, and long-term evaluation remain, the continued pursuit of innovation has the potential to transform outcomes for patients with T2DM and redefine the standard of care.

8. Conclusion

GLP-1 RAs and SGLT2 inhibitors have redefined the treatment paradigm for T2DM, offering multifaceted benefits beyond glycemic control. Their role in reducing cardiovascular and renal risks represents a major advancement in diabetes care. However, addressing challenges related to cost, accessibility, and long-term safety will be crucial to fully realizing their potential. As the field evolves, these agents are likely to become integral to personalized, patient-centered diabetes management.

Disclosure

Conceptualization, Agnieszka Parfianowicz, and Alicja Surma;

Methodology, Agnieszka Parfianowicz;

Software, Alicja Surma;

Check, Alicja Surma;

Formal analysis, Agnieszka Parfianowicz;

Investigation, Alicja Surma;

Resources, Alicja Surma;

Data curation, Agnieszka Parfianowicz;

Writing - rough preparation, Agnieszka Parfianowicz;

Writing - review and editing, Alicja Surma;

Visualization, Agnieszka Parfianowicz;

Supervision, Alicja Surma;

Project administration, Agnieszka Parafinowicz;

Receiving funding, Alicja Surma;

All authors have read and agreed with the published version of the manuscript.

Funding Statement:

The study did not receive special funding.

Institutional Review Board Statement:

Not applicable.

Informed Consent Statement:

Not applicable.

Data Availability Statement:

Not applicable.

Conflict of Interest Statement:

The authors declare no conflict of interest.

References:

1. *Diabetes Facts and Figures | International Diabetes Federation* , from https://idf.org/about-diabetes/diabetes-facts-figures/

2. Cole, J. B., & Florez, J. C. (2020). Genetics of diabetes and diabetes complications. *Nature Reviews. Nephrology*, *16*(7), 377. https://doi.org/10.1038/S41581-020-0278-5

3. Deshpande, A. D., Harris-Hayes, M., & Schootman, M. (2008). Epidemiology of Diabetes and Diabetes-Related Complications. *Physical Therapy*, *88*(11), 1254. https://doi.org/10.2522/PTJ.20080020

4. Demir, S., Nawroth, P. P., Herzig, S., & Ekim Üstünel, B. (2021). Emerging Targets in Type 2 Diabetes and Diabetic Complications. *Advanced Science*, *8*(18), 2100275. https://doi.org/10.1002/ADVS.202100275

5. Ruze, R., Liu, T., Zou, X., Song, J., Chen, Y., Xu, R., Yin, X., & Xu, Q. (2023). Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments. *Frontiers in Endocrinology*, *14*, 1161521. https://doi.org/10.3389/FENDO.2023.1161521

6. Pfeiffer, A. F. H., & Klein, H. H. (2014). The Treatment of Type 2 Diabetes. *Deutsches Ärzteblatt International*, *111*(5), 69. https://doi.org/10.3238/ARZTEBL.2014.0069

7. Wright, A. K., Carr, M. J., Kontopantelis, E., Leelarathna, L., Thabit, H., Emsley, R., Buchan, I., Mamas, M. A., van Staa, T. P., Sattar, N., Ashcroft, D. M., & Rutter, M. K. (2022). Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes. *Diabetes Care*, *45*(4), 909–918. https://doi.org/10.2337/DC21-1113

8. Kautzky-Willer, A., Harreiter, J., & Pacini, G. (2016). Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus. *Endocrine Reviews*, *37*(3), 278. https://doi.org/10.1210/ER.2015-1137

9. Lee, S. H., Park, S. Y., & Choi, C. S. (2021). Insulin Resistance: From Mechanisms to Therapeutic Strategies. *Diabetes & Metabolism Journal*, *46*(1), 15. https://doi.org/10.4093/DMJ.2021.0280

10. Petersen, M. C., & Shulman, G. I. (2018). Mechanisms of Insulin Action and Insulin Resistance. *Physiological Reviews*, *98*(4), 2133. https://doi.org/10.1152/PHYSREV.00063.2017

11. Masenga, S. K., Kabwe, L. S., Chakulya, M., & Kirabo, A. (2023). Mechanisms of Oxidative Stress in Metabolic Syndrome. *International Journal of Molecular Sciences*, *24*(9), 7898. https://doi.org/10.3390/IJMS24097898

12. Drucker, D. J. (2021). GLP-1 physiology informs the pharmacotherapy of obesity. *Molecular Metabolism*, *57*, 101351. https://doi.org/10.1016/J.MOLMET.2021.101351

13. Drucker, D. J. (2018). Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. *Cell Metabolism*, *27*(4), 740–756. https://doi.org/10.1016/J.CMET.2018.03.001

14. Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2020). GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. *Molecular Metabolism*, *46*, 101102. https://doi.org/10.1016/J.MOLMET.2020.101102

15. Holst, J. J. (2007). The physiology of glucagon-like peptide 1. *Physiological Reviews*, *87*(4), 1409–1439. https://doi.org/10.1152/PHYSREV.00034.2006

16. Gronda, E., Jessup, M., Iacoviello, M., Palazzuoli, A., & Napoli, C. (2020). Glucose Metabolism in the Kidney: Neurohormonal Activation and Heart Failure Development. *Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease*, *9*(23), e018889. https://doi.org/10.1161/JAHA.120.018889

17. Jiang, K., Xu, Y., Wang, D., Chen, F., Tu, Z., Qian, J., Xu, S., Xu, Y., Hwa, J., Li, J., Shang, H., & Xiang, Y. (2021). Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis. *Protein & Cell*, *13*(5), 336. https://doi.org/10.1007/S13238-020-00809-4

18. Ellison, D. H. (2021). SGLT2 inhibitors, hemodynamics, and kidney protection. *American Journal of Physiology - Renal Physiology*, *321*(1), F47. https://doi.org/10.1152/AJPRENAL.00092.2021

19. Taylor, S. I., Yazdi, Z. S., & Beitelshees, A. L. (2021). Pharmacological treatment of hyperglycemia in type 2 diabetes. *The Journal of Clinical Investigation*, *131*(2), e142243. https://doi.org/10.1172/JCI142243

20. Kahn, S. E., Cooper, M. E., & del Prato, S. (2013). PATHOPHYSIOLOGY AND TREATMENT OF TYPE 2 DIABETES: PERSPECTIVES ON THE PAST, PRESENT AND FUTURE. *Lancet*, *383*(9922), 1068. https://doi.org/10.1016/S0140-6736(13)62154-6

21. Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., Strauss, H. M., Gram, D. X., Knudsen, S. M., Nielsen,

F. S., Thygesen, P., Reedtz-Runge, S., & Kruse, T. (2015). Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. *Journal of Medicinal Chemistry*, *58*(18), 7370–7380. https://doi.org/10.1021/ACS.JMEDCHEM.5B00726/SUPPL_FILE/JM5B00726_SI_001.PDF

22. Kawai, T., Sun, B., Yoshino, H., Feng, D., Suzuki, Y., Fukazawa, M., Nagao, S., Wainscott, D. B., Showalter, A. D., Droz, B. A., Kobilka, T. S., Coghlan, M. P., Willard, F. S., Kawabe, Y., Kobilka, B. K., & Sloop, K. W. (2020). Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist. *Proceedings of the National Academy of Sciences of the United States of America*, *117*(47), 29959–29967. https://doi.org/10.1073/PNAS.2014879117/-/DCSUPPLEMENTAL

23. Danowitz, M., & de Leon, D. D. (2022). The Role of GLP-1 Signaling in Hypoglycemia due to Hyperinsulinism. *Frontiers in Endocrinology*, *13*, 863184. https://doi.org/10.3389/FENDO.2022.863184

24. Yao, H., Zhang, A., Li, D., Wu, Y., Wang, C. Z., Wan, J. Y., & Yuan, C. S. (2024). Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. *The BMJ*, *384*, e076410. https://doi.org/10.1136/BMJ-2023-076410

25. de Oca, alejandra P. Z. M. T. S., PelliTero, S., & PUig-DoMingo, M. (2021). obesity and glP-1. *Minerva Endocrinology*, *46*(2), 168–176. https://doi.org/10.23736/S2724-6507.20.03369-6

26. Kadouh, H., Chedid, V., Halawi, H., Burton, D. D., Clark, M. M., Khemani, D., Vella, A., Acosta, A., & Camilleri, M. (2019). GLP-1 Analog Modulates Appetite, Taste Preference, Gut Hormones, and Regional Body Fat Stores in Adults with Obesity. *The Journal of Clinical Endocrinology and Metabolism*, *105*(5), 1552. https://doi.org/10.1210/CLINEM/DGZ140

27. Wang, J. Y., Wang, Q. W., Yang, X. Y., Yang, W., Li, D. R., Jin, J. Y., Zhang, H. C., & Zhang, X. F. (2023). GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach. *Frontiers in Endocrinology*, *14*, 1085799. https://doi.org/10.3389/FENDO.2023.1085799

28. Marx, N., Husain, M., Lehrke, M., Verma, infodh, & Sattar, N. (2022). GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients with Type 2 Diabetes. *Circulation*, *146*(24), 1882–1894. https://doi.org/10.1161/CIRCULATIONAHA.122.059595/ASSET/AD09F9FB-0BF4-4C02-8C15-FE4DF1F5A441/ASSETS/GRAPHIC/CIRCULATIONAHA.122.059595.FIG01.JPG

29. Vallon, V., & Verma, S. (2020). Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function. *Annual Review of Physiology*, *83*, 503. https://doi.org/10.1146/ANNUREV-PHYSIOL-031620-095920

30. Bailey, C. J., Day, C., & Bellary, S. (2022). Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease. *Current Diabetes Reports*, *22*(1), 39. https://doi.org/10.1007/S11892-021-01442-Z

31. Chen, S., Coronel, R., Hollmann, M. W., Weber, N. C., & Zuurbier, C. J. (2022). Direct cardiac effects of SGLT2 inhibitors. *Cardiovascular Diabetology*, *21*(1), 45. https://doi.org/10.1186/S12933-022-01480-1

32. Beal, B., Schutte, A. E., & Neuen, B. L. (2023). Blood Pressure Effects of SGLT2 Inhibitors: Mechanisms and Clinical Evidence in Different Populations. *Current Hypertension Reports*, *25*(12), 429–435. https://doi.org/10.1007/S11906-023-01281-1/METRICS

33. Brown, E., Wilding, J. P. H., Barber, T. M., Alam, U., & Cuthbertson, D. J. (2019). Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities. *Obesity Reviews*, *20*(6), 816–828. https://doi.org/10.1111/OBR.12841

34. Steiner, S. (2016). Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *Zeitschrift Fur Gefassmedizin*, *13*(1), 17–18. https://doi.org/10.1056/NEJMOA1504720/SUPPL_FILE/NEJMOA1504720_DISCLOSURES.PDF

35. McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., Böhm, M., Chiang, C.-E., Chopra, V. K., Boer, R. A. de, Desai, A. S., Diez, M., Drozdz, J., Dukát, A., Ge, J., … Langkilde, A.-M. (2019). Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. *New England Journal of Medicine*, *381*(21), 1995–2008. https://doi.org/10.1056/NEJMOA1911303

36. Toyama, T., Neuen, B. L., Jun, M., Ohkuma, T., Neal, B., Jardine, M. J., Heerspink, H. L., Wong, M. G., Ninomiya, T., Wada, T., & Perkovic, V. (2019). Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis. *Diabetes, Obesity and Metabolism*, *21*(5), 1237–1250. https://doi.org/10.1111/DOM.13648

37. Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., Cannon, C. P., Capuano, G., Chu, P.-L., de Zeeuw, D., Greene, T., Levin, A., Pollock, C., Wheeler, D. C., Yavin, Y., … Mahaffey, K. W. (2019). Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. *New England Journal of Medicine*, *380*(24), 2295–2306. https://doi.org/10.1056/NEJMOA1811744/SUPPL_FILE/NEJMOA1811744_DATA-SHARING.PDF

38. Podestà, M. A., Sabiu, G., Galassi, A., Ciceri, P., & Cozzolino, M. (2023). SGLT2 Inhibitors in Diabetic and Non-Diabetic Chronic Kidney Disease. *Biomedicines*, *11*(2), 279. https://doi.org/10.3390/BIOMEDICINES11020279

39. Theodorakopoulou, M. P., & Sarafidis, P. (2023). SGLT2 inhibitors and finerenone in non-diabetic CKD: a step into the (near) future? *Clinical Kidney Journal*, *17*(1), sfad272. https://doi.org/10.1093/CKJ/SFAD272

40. Theofilis, P., Sagris, M., Oikonomou, E., Antonopoulos, A. S., Siasos, G., Tsioufis, K., & Tousoulis, D. (2022). Pleiotropic effects of SGLT2 inhibitors and heart failure outcomes. *Diabetes Research and Clinical Practice*, *188*.

https://doi.org/10.1016/J.DIABRES.2022.109927/ASSET/4E388F00-030C-4E59-8E2B-894802B1E2CD/MAIN.ASSETS/GA1.JPG

41. Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., Steinberg, W. M., Stockner, M., Zinman, B., Bergenstal, R. M., & Buse, J. B. (2016). Liraglutide and cardiovascular outcomes in type 2 diabetes. *Drug and Therapeutics Bulletin*, *54*(9), 101. https://doi.org/10.1056/NEJMOA1603827/SUPPL_FILE/NEJMOA1603827_DISCLOSURES.PDF

42. Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., Woo, V., Hansen, O., Holst, A. G., Pettersson, J., & Vilsbøll, T. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. *New England Journal of Medicine*, *375*(19), 1834–1844. https://doi.org/10.1056/NEJMOA1607141/SUPPL_FILE/NEJMOA1607141_DISCLOSURES.PDF

43. Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019). Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. *The Lancet Diabetes and Endocrinology*, *7*(10), 776–785. https://doi.org/10.1016/S2213-8587(19)30249-9

44. Lytvyn, Y., Bjornstad, P., Udell, J. A., Lovshin, J. A., & Cherney, D. Z. I. (2017). Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications and Summary of Clinical Trials. *Circulation*, *136*(17), 1643. https://doi.org/10.1161/CIRCULATIONAHA.117.030012

45. Goldney, J., Sargeant, J. A., & Davies, M. J. (2023). Incretins and microvascular complications of diabetes: neuropathy, nephropathy, retinopathy and microangiopathy. *Diabetologia*, *66*(10), 1832. https://doi.org/10.1007/S00125-023-05988-3

46. Vallon, V., & Thomson, S. C. (2020). The tubular hypothesis of nephron filtration and diabetic kidney disease. *Nature Reviews. Nephrology*, *16*(6), 317. https://doi.org/10.1038/S41581-020-0256-Y

47. Heerspink, H. J. L., Stefánsson, B. v., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., Sjöström, C. D., Toto, R. D., Langkilde, A.-M., & Wheeler, D. C. (2020). Dapagliflozin in Patients with Chronic Kidney Disease. *New England Journal of Medicine*, *383*(15), 1436–1446. https://doi.org/10.1056/NEJMOA2024816/SUPPL_FILE/NEJMOA2024816_DATA-SHARING.PDF

48. Moore, P. W., Malone, K., VanValkenburg, D., Rando, L. L., Williams, B. C., Matejowsky, H. G., Ahmadzadeh, S., Shekoohi, S., Cornett, E. M., & Kaye, A. D. (2023). GLP-1 Agonists for Weight Loss: Pharmacology and Clinical Implications. *Advances in Therapy*, *40*(3), 723–742. https://doi.org/10.1007/S12325-022-02394-W/METRICS

49. Rieg, T., & Vallon, V. (2018). Development of SGLT1 and SGLT2 inhibitors. *Diabetologia*, *61*(10), 2079. https://doi.org/10.1007/S00125-018-4654-7

50. Knudsen, L. B., & Lau, J. (2019). The Discovery and Development of Liraglutide and Semaglutide. *Frontiers in Endocrinology*, *10*(APR), 155. https://doi.org/10.3389/FENDO.2019.00155

51. Benham, J. L., Booth, J. E., Sigal, R. J., Daskalopoulou, S. S., Leung, A. A., & Rabi, D. M. (2021). Systematic review and meta-analysis: SGLT2 inhibitors, blood pressure and cardiovascular outcomes. *International Journal of Cardiology. Heart & Vasculature*, *33*, 100725. https://doi.org/10.1016/J.IJCHA.2021.100725

52. Bendotti, G., Montefusco, L., Lunati, M. E., Usuelli, V., Pastore, I., Lazzaroni, E., Assi, E., Seelam, A. J., el Essawy, B., Jang, Y., Loretelli, C., D'Addio, F., Berra, C., ben Nasr, M., Zuccotti, G. V., & Fiorina, P. (2022). The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists. *Pharmacological Research*, *182*, 106320. https://doi.org/10.1016/J.PHRS.2022.106320

53. Heimke, M., Lenz, F., Rickert, U., Lucius, R., & Cossais, F. (2022). Anti-Inflammatory Properties of the SGLT2 Inhibitor Empagliflozin in Activated Primary Microglia. *Cells*, *11*(19), 3107. https://doi.org/10.3390/CELLS11193107

54. Wharton, S., Davies, M., Dicker, D., Lingvay, I., Mosenzon, O., Rubino, D. M., & Pedersen, S. D. (2022). Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. *Postgraduate Medicine*, *134*(1), 14–19. https://doi.org/10.1080/00325481.2021.2002616

55. Filippatos, T. D., Panagiotopoulou, T. v., & Elisaf, M. S. (2015). Adverse Effects of GLP-1 Receptor Agonists. *The Review of Diabetic Studies : RDS*, *11*(3), 202. https://doi.org/10.1900/RDS.2014.11.202

56. Kittipibul, V., Cox, Z. L., Chesdachai, S., Fiuzat, M., Lindenfeld, J. A., & Mentz, R. J. (2024). Genitourinary Tract Infections in Patients Taking SGLT2 Inhibitors: JACC Review Topic of the Week. *Journal of the American College of Cardiology*, *83*(16), 1568–1578. https://doi.org/10.1016/J.JACC.2024.01.040

57. Musso, G., Saba, F., Cassader, M., & Gambino, R. (2020). Diabetic ketoacidosis with SGLT2 inhibitors. *BMJ*, *371*, 1–4. https://doi.org/10.1136/BMJ.M4147

58. Tentolouris, A., Vlachakis, P., Tzeravini, E., Eleftheriadou, I., & Tentolouris, N. (2019). SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects. *International Journal of Environmental Research and Public Health*, *16*(16), 2965. https://doi.org/10.3390/IJERPH16162965

59. Cusick, M. M., Tisdale, R. L., Chertow, G. M., Owens, D. K., & Goldhaber-Fiebert, J. D. (2023). Population-Wide Screening for Chronic Kidney Disease: a Cost-Effectiveness Analysis. *Annals of Internal Medicine*, *176*(6), 788. https://doi.org/10.7326/M22-3228

60. Garcia-Ropero, A., Badimon, J. J., & Santos-Gallego, C. G. (2018). The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments. *Expert Opinion on Drug Metabolism & Toxicology*, *14*(12), 1287–1302. https://doi.org/10.1080/17425255.2018.1551877

61. Andreea, M. M., Surabhi, S., Razvan-Ionut, P., Lucia, C., Camelia, N., Emil, T., & Tiberiu, N. I. (2023). Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits? *Medicina*, *59*(4), 742. https://doi.org/10.3390/MEDICINA59040742

62. Davies, M., Pieber, T. R., Hartoft-Nielsen, M. L., Hansen, O. K. H., Jabbour, S., & Rosenstock, J. (2017). Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial. *JAMA*, *318*(15), 1460. https://doi.org/10.1001/JAMA.2017.14752

63. Wright, E. M. (2021). SGLT2 Inhibitors: Physiology and Pharmacology. *Kidney360*, *2*(12), 2027–2037. https://doi.org/10.34067/KID.0002772021/-/DCSUPPLEMENTAL

64. Forzano, I., Varzideh, F., Avvisato, R., Jankauskas, S. S., Mone, P., & Santulli, G. (2022). Tirzepatide: A Systematic Update. *International Journal of Molecular Sciences*, *23*(23). https://doi.org/10.3390/IJMS232314631

65. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. *New England Journal of Medicine*, *387*(3), 205–216. https://doi.org/10.1056/NEJMOA2206038/SUPPL_FILE/NEJMOA2206038_DATA-SHARING.PDF

66. Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. *New England Journal of Medicine*, *385*(6), 503–515. https://doi.org/10.1056/NEJMOA2107519/SUPPL_FILE/NEJMOA2107519_DATA-SHARING.PDF

67. Bailey, C. J., & Day, C. (2019). The future of new drugs for diabetes management. *Diabetes Research and Clinical Practice*, *155*. https://doi.org/10.1016/J.DIABRES.2019.107785/ASSET/A063AB85-C1DD-4E92-9AED-5199F9692EFD/MAIN.ASSETS/GR2.SML

68. Lüscher, T. F. (2020). A revolution in diabetes care: novel drugs and new recommendations. *European Heart Journal*, *41*(2), 195–198. https://doi.org/10.1093/EURHEARTJ/EHZ966

69. Ljubic, B., Hai, A. A., Stanojevic, M., Diaz, W., Polimac, D., Pavlovski, M., & Obradovic, Z. (2020). Predicting complications of diabetes mellitus using advanced machine learning algorithms. *Journal of the American Medical Informatics Association : JAMIA*, *27*(9), 1343. https://doi.org/10.1093/JAMIA/OCAA120

70. Anderson, A. E., Kerr, W. T., Thames, A., Li, T., Xiao, J., & Cohen, M. S. (2015). Electronic health record phenotyping improves detection and screening of type 2 diabetes in

the general United States population: A cross-sectional, unselected, retrospective study. *Journal of Biomedical Informatics*, *60*, 162. https://doi.org/10.1016/J.JBI.2015.12.006

71. Li, S. (2023). Effective and Cost-Conscious Utilization of SGLT2 Inhibitors: Are Risk Scores the Answer? *JACC: Heart Failure*, *11*(7), 836–837. https://doi.org/10.1016/J.JCHF.2023.05.008

72. Choi, J. G., Winn, A. N., Skandari, M. R., Franco, M. I., Staab, E. M., Alexander, J., Wan, W., Zhu, M., Huang, E. S., Philipson, L., & Laiteerapong, N. (2022). First-Line Therapy for Type 2 Diabetes With Sodium–Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists: A Cost-Effectiveness Study. *Annals of Internal Medicine*, *175*(10), 1392. https://doi.org/10.7326/M21-2941